1 file | 1.69 MB

# External validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy

PATRICK PEETERS (UGent) , Wim Van Biesen (UGent) , Nic Veys (UGent)
(2016) 17.
Author
Organization
Abstract
BACKGROUND: Shared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients starting renal replacement therapy in Flanders. METHODS: During 3 years (2001-2003), the data set collected for the Nederlandstalige Belgische Vereniging voor Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated REIN score(aREIN), being the REIN score without the parameter "mobility", was calculated, and prognostication of mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated. RESULTS: Three thousand four hundred seventy-two patients started RRT in Flanders during the observation period (mean age 67.6 ± 14.3, 56.7 % men, 33.6 % diabetes). The mean aREIN score was 4.1 ± 2.8, and 56.8, 23.1, 12.6 and 7.4 % of patients had a score of ≤4, 5-6, 7-8 or ≥9 respectively. Mortality at 3, 6 and 12 months was 8.6, 14.1 and 19.6 % in the overall and 13.2, 21.5 and 31.9 % in the group with age >75 respectively. In RoC analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an incremental increase in mortality with the aREIN score from 5.6 to 45.8 % mortality at 6 months for those with a score ≤4 or ≥9 respectively. CONCLUSION: The aREIN score is a useful tool to predict short term prognosis of patients starting renal replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making on whether or not start of dialysis is worthwhile.
Keywords
CHRONIC KIDNEY-DISEASE, CONSERVATIVE CARE, UNITED-STATES, DIALYSIS, PHYSICIANS, SURVIVAL, OCTOGENARIANS, PERCEPTIONS, ADULTS, LIFE

• External Validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy..pdf
• full text
• |
• open access
• |
• PDF
• |
• 1.69 MB

## Citation

Chicago
PEETERS, PATRICK, Wim Van Biesen, Nic Veys, Wim Lemahieu, Bart De Moor, and Johan De Meester. 2016. “External Validation of a Risk Stratification Model to Assist Shared Decision Making for Patients Starting Renal Replacement Therapy.” Bmc Nephrology 17.
APA
PEETERS, P., Van Biesen, W., Veys, N., Lemahieu, W., De Moor, B., & De Meester, J. (2016). External validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy. BMC NEPHROLOGY, 17.
Vancouver
1.
PEETERS P, Van Biesen W, Veys N, Lemahieu W, De Moor B, De Meester J. External validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy. BMC NEPHROLOGY. 2016;17.
MLA
PEETERS, PATRICK, Wim Van Biesen, Nic Veys, et al. “External Validation of a Risk Stratification Model to Assist Shared Decision Making for Patients Starting Renal Replacement Therapy.” BMC NEPHROLOGY 17 (2016): n. pag. Print.
@article{7184100,
abstract     = {BACKGROUND: Shared decision making is nowadays acknowledged as an essential step when deciding on starting renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients starting renal replacement therapy in Flanders.
METHODS: During 3 years (2001-2003), the data set collected for the Nederlandstalige Belgische Vereniging voor Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated REIN score(aREIN), being the REIN score without the parameter {\textacutedbl}mobility{\textacutedbl}, was calculated, and prognostication of mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated.
RESULTS: Three thousand four hundred seventy-two patients started RRT in Flanders during the observation period (mean age 67.6\,{\textpm}\,14.3, 56.7 \% men, 33.6 \% diabetes). The mean aREIN score was 4.1\,{\textpm}\,2.8, and 56.8, 23.1, 12.6 and 7.4 \% of patients had a score of \ensuremath{\leq}4, 5-6, 7-8 or \ensuremath{\geq}9 respectively. Mortality at 3, 6 and 12 months was 8.6, 14.1 and 19.6 \% in the overall and 13.2, 21.5 and 31.9 \% in the group with age {\textrangle}75 respectively. In RoC analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an incremental increase in mortality with the aREIN score from 5.6 to 45.8 \% mortality at 6 months for those with a score \ensuremath{\leq}4 or \ensuremath{\geq}9 respectively.
CONCLUSION: The aREIN score is a useful tool to predict short term prognosis of patients starting renal replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making on whether or not start of dialysis is worthwhile.},
articleno    = {41},
author       = {PEETERS, PATRICK and Van Biesen, Wim and Veys, Nic and Lemahieu, Wim and De Moor, Bart and De Meester, Johan},
issn         = {1471-2369},
journal      = {BMC NEPHROLOGY},